Skip to main content

Table 2 Burden of ICC attributable to HPV 16/18 and HPV 31/33/45/52/58 in 2012, projected to 2025; by region

From: Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease

Region

HPV RC (%)

Attributable new cases (N)

16/18

31/33/45/ 52/58

Year 2012

Year 2025

16/18

31/33/45/ 52/58

16/18

31/33/45/52/58

World

70.8

18.6

391,016

102,172

444,167

116,061

Africa

70.3

16.7

60,925

14,438

80,556

19,090

Asia

71.7

19.8

232,046

63,986

259,130

71,454

 Eastern Asia

68.9

22.3

95,505

30,869

100,950

32,629

 Western/Central Asia

77.5

14.5

145,101

27,073

171,333

31,967

Latin-America

68.3

19.8

48,777

14,142

54,973

15,938

 South America

69.4

19.6

34,632

9,799

38,783

10,973

 Central America

64.4

20.2

13,602

4,264

15,522

4,866

North America

78.7

16.6

9,913

2,094

10,913

2,305

Europe

72.8

16.2

39,880

8,867

39,924

8,877

Oceania

78.5

8.8

1,346

152

1,587

179

  1. * We assume that almost all cervical cancer cases are caused by HPV infection, and thus almost 100% of cervical cancer cases are attributable to HPV infection.
  2. "ICC": Invasive cervical cancer; “RC”: Relative Contribution; “N”: Number of new cases diagnosed of cervical cancer each year.
  3. Estimated number of new ICC cases is based on GLOBOCAN 2008 estimates and World Population Prospects (2010 revision). Impact of vaccination has not been taken into account for the calculations of 2025 projections.
  4. Specific information on HPV 6 and 11 is not included due to low relative contribution of these types.
Back to article page

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us